Published online May 1, 2006
PEDIATRICS Vol. 117 No. 5 May 2006, pp. S350-S354 (doi:10.1542/peds.2005-2633O)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alexander, D.
Right arrow Articles by van Dyck, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alexander, D.
Right arrow Articles by van Dyck, P. C.
Related Collections
Right arrow Premature & Newborn

SUPPLEMENT ARTICLE

A Vision of the Future of Newborn Screening

Duane Alexander, MDa and Peter C. van Dyck, MD, MPH, FAAPb

a National Institutes of Health, Bethesda, Maryland
b Health Resources and Services Administration, Rockville, Maryland

In 40 years, newborn screening has evolved to become a standard component of preventive public health. Despite its widespread acceptance, efforts need to be made to overcome some significant problems. There is inequity in the conditions for which states screen routinely, and many conditions that could be screened for are not, for economic or logistic reasons. Existing (tandem mass spectrometry) and potential (DNA microarray) technologies could be developed and put in place to correct these existing shortcomings. To do so will require investment in the technologies, combined with public and professional education and provision of a high-quality, accessible system for confirmation of diagnoses, family counseling, initiation of treatment, and the opportunity to participate in research to develop new or improved therapies.

Key Words: newborn screening • recommendations

Abbreviations: NIH—National Institutes of Health • HRSA—Health Resources and Services Administration • MCHB—Maternal and Child Health Bureau • NICHD—National Institute of Child Health and Human Development

Accepted Dec 27, 2005.




This article has been cited by other articles:


Home page
 J Pediatr PsycholHome page
B. Wilfond and L. F. Ross
From Genetics to Genomics: Ethics, Policy, and Parental Decision-making
J. Pediatr. Psychol., July 22, 2008; (2008) jsn075v1.
[Abstract] [Full Text] [PDF]

Home page
 J Law Med EthicsHome page
E. W. Clayton
Incidental findings in genetics research using archived DNA.
J. Law Med. Ethics, June 1, 2008; 36(2): 286 - 291.
[PDF]

Home page
 PediatricsHome page
N. J. Kerruish, P. L. Campbell-Stokes, A. Gray, T. R. Merriman, S. P. Robertson, and B. J. Taylor
Maternal Psychological Reaction to Newborn Genetic Screening for Type 1 Diabetes
Pediatrics, August 1, 2007; 120(2): e324 - e335.
[Abstract] [Full Text] [PDF]